Cryocell International Stock Return On Equity
| CCEL Stock | USD 6.20 0.02 0.32% |
CryoCell International fundamentals help investors to digest information that contributes to CryoCell International's financial success or failures. It also enables traders to predict the movement of CryoCell Stock. The fundamental analysis module provides a way to measure CryoCell International's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to CryoCell International stock.
| Last Reported | Projected for Next Year | ||
| Return On Equity | 0.99 | 1.04 |
CryoCell | Return On Equity |
CryoCell International Company Return On Equity Analysis
CryoCell International's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current CryoCell International Return On Equity | 1.29 |
Most of CryoCell International's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, CryoCell International is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
CryoCell Return On Equity Driver Correlations
Understanding the fundamental principles of building solid financial models for CryoCell International is extremely important. It helps to project a fair market value of CryoCell Stock properly, considering its historical fundamentals such as Return On Equity. Since CryoCell International's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of CryoCell International's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of CryoCell International's interrelated accounts and indicators.
Click cells to compare fundamentals
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
CryoCell Total Stockholder Equity
Total Stockholder Equity |
|
Based on the latest financial disclosure, CryoCell International has a Return On Equity of 1.292. This is 105.39% lower than that of the Health Care Providers & Services sector and significantly higher than that of the Health Care industry. The return on equity for all United States stocks is notably lower than that of the firm.
CryoCell Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses CryoCell International's direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of CryoCell International could also be used in its relative valuation, which is a method of valuing CryoCell International by comparing valuation metrics of similar companies.CryoCell International is currently under evaluation in return on equity category among its peers.
CryoCell International Current Valuation Drivers
We derive many important indicators used in calculating different scores of CryoCell International from analyzing CryoCell International's financial statements. These drivers represent accounts that assess CryoCell International's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of CryoCell International's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 54.1M | 100.7M | 37.0M | 44.6M | 40.2M | 28.6M | |
| Enterprise Value | 50.0M | 95.3M | 46.9M | 55.1M | 63.4M | 60.2M |
CryoCell International ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, CryoCell International's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to CryoCell International's managers, analysts, and investors.Environmental | Governance | Social |
CryoCell Fundamentals
| Return On Equity | 1.29 | ||||
| Return On Asset | -0.0013 | ||||
| Profit Margin | (0.28) % | ||||
| Operating Margin | 0.17 % | ||||
| Current Valuation | 59.59 M | ||||
| Shares Outstanding | 8.06 M | ||||
| Shares Owned By Insiders | 47.46 % | ||||
| Shares Owned By Institutions | 11.12 % | ||||
| Number Of Shares Shorted | 9.45 K | ||||
| Price To Earning | 10.76 X | ||||
| Price To Book | 9.72 X | ||||
| Price To Sales | 1.60 X | ||||
| Revenue | 31.34 M | ||||
| Gross Profit | 21.54 M | ||||
| EBITDA | 5.2 M | ||||
| Net Income | (9.52 M) | ||||
| Cash And Equivalents | 2.96 M | ||||
| Cash Per Share | 0.35 X | ||||
| Total Debt | 10.9 M | ||||
| Debt To Equity | 0.26 % | ||||
| Current Ratio | 0.47 X | ||||
| Book Value Per Share | (1.19) X | ||||
| Cash Flow From Operations | 8.92 M | ||||
| Short Ratio | 2.91 X | ||||
| Earnings Per Share | (1.07) X | ||||
| Target Price | 9.0 | ||||
| Number Of Employees | 82 | ||||
| Beta | 0.53 | ||||
| Market Capitalization | 49.99 M | ||||
| Total Asset | 61.22 M | ||||
| Retained Earnings | (31.16 M) | ||||
| Working Capital | (11.41 M) | ||||
| Current Asset | 6.08 M | ||||
| Current Liabilities | 2.82 M | ||||
| Net Asset | 61.22 M |
About CryoCell International Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze CryoCell International's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of CryoCell International using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of CryoCell International based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out CryoCell International Piotroski F Score and CryoCell International Altman Z Score analysis. For more information on how to buy CryoCell Stock please use our How to buy in CryoCell Stock guide.You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CryoCell International. If investors know CryoCell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CryoCell International listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.625 | Earnings Share (1.07) | Revenue Per Share 3.89 | Quarterly Revenue Growth 0.025 | Return On Assets (0) |
The market value of CryoCell International is measured differently than its book value, which is the value of CryoCell that is recorded on the company's balance sheet. Investors also form their own opinion of CryoCell International's value that differs from its market value or its book value, called intrinsic value, which is CryoCell International's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CryoCell International's market value can be influenced by many factors that don't directly affect CryoCell International's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CryoCell International's value and its price as these two are different measures arrived at by different means. Investors typically determine if CryoCell International is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CryoCell International's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.